Britain has approved the first drug based on a novel gene-editing technology, authorizing Boston’s Vertex Pharmaceuticals ... inherited blood disorders sickle cell disease and beta thalassemia.

Vertex Pharmaceuticals ... Casgevy, a CRISPR/Cas9 gene-edited cell therapy, is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Vertex is currently launching Casgevy for sickle cell disease (SCD). This is a 60/40 program partnered with CRISPR Therapeutics (CRSP). Data suggests the treatment is functionally curative.

The first gene therapies for sickle cell disease are now approved: Casgevy from Vertex Pharmaceuticals Casgevy and Lyfgenia from Bluebird Bio. Despite the same-day approval, key differences give ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only ... BEAM) $1.8 billion Sickle cell disease, alpha-1 antitrypsin deficiency, glycogen storage disease 1a, T-cell leukemia ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...